Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 11,15€(+21,99%). Der Median liegt bei 8,64€(−5,47%).
| Kaufen | 6 |
| Halten | 12 |
| Verkaufen | 1 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Aton Reports Further High Grade Diamond Drilling Results From Abu Marawat, Including 33.86 g/t Gold and 419 g/t Silver Over 2.5 Metres From the Fin Vein, and 44.59 g/t Gold and 103 g/t Silver Over 1.6 Metres From the J Vein
VANCOUVER, BC / ACCESS Newswire / July 9, 2025 / Aton Resources Inc. (TSXV:AAN) ("Aton" or the "Company") updates investors on the results of its diamond drilling programme at the Abu Marawat deposit ("Abu Marawat"), located within the retained exploration areas of the Company's Abu Marawat Concession (the "Concession") in the Eastern Desert of Egypt. Highlights: The diamond drilling programme at Abu Marawat has now been completed, with 113 holes drilled for a total of 9,642.7 metres.» Mehr auf accessnewswire.com
Aton Reports Further Diamond Drilling Results From Abu Marawat, Including 8.52 g/t Gold and 88.7 g/t Silver Over 15.4 Metres, and 6.06 g/t Gold and 59.6 g/t Silver Over 17.3 Metres
VANCOUVER, BC / ACCESS Newswire / May 20, 2025 / Aton Resources Inc. (TSXV:AAN) ("Aton" or the "Company") updates investors on the results of its ongoing diamond drilling programme at the Abu Marawat deposit ("Abu Marawat"), located within the retained exploration areas of the Company's Abu Marawat Concession (the "Concession") in the Eastern Desert of Egypt. Highlights: To date 95 diamond drill holes have been drilled at Abu Marawat, for a total of 7,917m.» Mehr auf accessnewswire.com
argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP
ADAPT-NXT data demonstrate consistent, sustained disease control across dosing schedules, further supporting individualized VYVGART dosing for gMG patients ADHERE+ oral presentation features long-term CIDP data demonstrating VYVGART Hytrulo's durable efficacy, sustained functional improvements and favorable safety profile argenx continues to advance a robust neuromuscular pipeline of clinical candidates; first-in-human data of ARGX-119 (MuSK agonist) support pipeline-in-a-product development plan April 8, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the presentation of 15 abstracts, including an oral presentation, at the 2025 American Academy of Neurology (AAN) Annual Meeting from April 5 – 9, 2025 in San Diego, CA. The presentations showcase long-term data of VYVGART® (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) demonstrating sustained disease control of generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) with a favorable safety profile.» Mehr auf globenewswire.com
Historische Dividenden
Alle Dividenden KennzahlenUnternehmenszahlen
| (EUR) | Juni 2024 | |
|---|---|---|
| Umsatz | 468,68 Mio | - |
| Bruttoeinkommen | 251,08 Mio | - |
| Nettoeinkommen | −11,09 Mio | - |
| EBITDA | 138,01 Mio | - |
Fundamentaldaten
| Metrik | Wert |
|---|---|
Marktkapitalisierung | 272,32 Mio€ |
Anzahl Aktien | 31,55 Mio |
52 Wochen-Hoch/Tief | 10,18€ - 5,66€ |
Dividendenrendite | 1,24% |
Dividenden TTM | 0,11€ |
Beta | 1,42 |
KGV (PE Ratio) | −8,08 |
KGWV (PEG Ratio) | 0,11 |
KBV (PB Ratio) | 0,47 |
KUV (PS Ratio) | 0,16 |
Unternehmensprofil
The Aaron's Company, Inc. bietet Lease-to-Own- und Kauflösungen an. Das Unternehmen verkauft und verleast Möbel, Haushaltsgeräte, Elektronik, Computer und Zubehör über firmeneigene und Franchise-Geschäfte in den Vereinigten Staaten und Kanada sowie über seine E-Commerce-Plattform direkt an Verbraucher. Außerdem produziert und liefert das Unternehmen Bettwaren und Polstermöbel. Zum 31. Dezember 2021 betrieb das Unternehmen 1.074 Filialen und 236 unabhängige Franchisegeschäfte. Das Unternehmen war früher unter dem Namen Aaron's SpinCo, Inc. bekannt. The Aaron's Company, Inc. wurde 1955 gegründet und hat seinen Hauptsitz in Atlanta, Georgia.
| Name | AARON'S COMPANY INC. O.N. |
| CEO | Douglas A. Lindsay |
| Sitz | Atlanta, ga USA |
| Website | |
| Industrie | Energiezubehör- und dienste |
| Börsengang | |
| Mitarbeiter | 9.071 |
Ticker Symbole
| Börse | Symbol |
|---|---|
NYSE | AAN |
Assets entdecken
Shareholder von AARON'S COMPANY INC. O.N. investieren auch in folgende Assets
